

Yale SCHOOL OF MEDICINE

**Yale Pediatric Ethics Program** *presents*

# Ethical Considerations of Next Generation Fetal Therapies

**Christy L. Cummings, MD**

*Neonatologist | Ethics Associate*

*Assistant Professor of Pediatrics, Harvard Medical School*

*Director of Medical Ethics & Humanities, Newborn Medicine*

*Boston Children's Hospital, Division of Newborn Medicine*



**Thursday, January 9, 2020**

**5:00 – 6:30 PM**

**Cohen Auditorium**

Yale Child Study Center, NIHB, E-02

230 South Frontage Road, New Haven

**RSVP by January 6th** to

203.737.5943 or [karen.kolb@yale.edu](mailto:karen.kolb@yale.edu)

Refreshments and light fare.

**This program is jointly sponsored with JDT Hospice Institute.**

**Accreditation:** This Activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The John D. Thompson Hospice Institute for Education, Training, and Research, Inc., and The Yale School of Medicine's Pediatric Ethics Program. The John D. Thompson Hospice Institute for Education, Training and Research, Inc. is accredited by ACCME to provide continuing medical education for physicians. The John D. Thompson Hospice Institute for Education, Training and Research, Inc. has designated this educational activity for **1.5 AMA PRA Category 1 Credits (CMEs)**.

The John D. Thompson Hospice Institute for Education, Training and Research, Inc. is an Approved Provider of Continuing Nursing Education by the Northeast Multistate Division, an Accredited Approver by the American Nursing Credentialing Center's Commission on Accreditation. This program has been designated for **1.5 Contact Hours (CEUs)**.

This program has been approved for Continuing Education Credit Hours by the National Association of Social Workers, CT and meets the continuing education criteria for CT Social Worker Licensure renewal and has been designated for **1.5 CEUs**.

**DISCLOSURE:** The speakers and all Planning Committee Members have made full disclosure and do not have any commercial or financial interests that would bias this program in any way.